EA201992322A3 - Соединения и композиции для лечения гематологических расстройств - Google Patents
Соединения и композиции для лечения гематологических расстройствInfo
- Publication number
- EA201992322A3 EA201992322A3 EA201992322A EA201992322A EA201992322A3 EA 201992322 A3 EA201992322 A3 EA 201992322A3 EA 201992322 A EA201992322 A EA 201992322A EA 201992322 A EA201992322 A EA 201992322A EA 201992322 A3 EA201992322 A3 EA 201992322A3
- Authority
- EA
- Eurasian Patent Office
- Prior art keywords
- compounds
- hematological disorders
- compositions
- treatment
- flt
- Prior art date
Links
- 150000001875 compounds Chemical class 0.000 title abstract 2
- 230000002489 hematologic effect Effects 0.000 title 1
- 239000000203 mixture Substances 0.000 title 1
- FSPQCTGGIANIJZ-UHFFFAOYSA-N 2-[[(3,4-dimethoxyphenyl)-oxomethyl]amino]-4,5,6,7-tetrahydro-1-benzothiophene-3-carboxamide Chemical compound C1=C(OC)C(OC)=CC=C1C(=O)NC1=C(C(N)=O)C(CCCC2)=C2S1 FSPQCTGGIANIJZ-UHFFFAOYSA-N 0.000 abstract 1
- 208000031261 Acute myeloid leukaemia Diseases 0.000 abstract 1
- 101000977771 Homo sapiens Interleukin-1 receptor-associated kinase 4 Proteins 0.000 abstract 1
- 102100023533 Interleukin-1 receptor-associated kinase 4 Human genes 0.000 abstract 1
- 208000033776 Myeloid Acute Leukemia Diseases 0.000 abstract 1
- 102100020718 Receptor-type tyrosine-protein kinase FLT3 Human genes 0.000 abstract 1
- 101710151245 Receptor-type tyrosine-protein kinase FLT3 Proteins 0.000 abstract 1
- 208000014951 hematologic disease Diseases 0.000 abstract 1
- 150000003839 salts Chemical class 0.000 abstract 1
- 150000001420 substituted heterocyclic compounds Chemical class 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
- A61K31/5375—1,4-Oxazines, e.g. morpholine
- A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/415—1,2-Diazoles
- A61K31/416—1,2-Diazoles condensed with carbocyclic ring systems, e.g. indazole
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/42—Oxazoles
- A61K31/422—Oxazoles not condensed and containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
- A61K31/437—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having nitrogen as a ring hetero atom, e.g. indolizine, beta-carboline
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
- A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
- A61K31/444—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring heteroatom, e.g. amrinone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/445—Non condensed piperidines, e.g. piperocaine
- A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
- A61K31/4545—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring hetero atom, e.g. pipamperone, anabasine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
- A61K31/5355—Non-condensed oxazines and containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Epidemiology (AREA)
- Hematology (AREA)
- Oncology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
- Plural Heterocyclic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Medicinal Preparation (AREA)
Abstract
Настоящее изобретение относится к способам лечения гематологических нарушений, таких как острый миелоидный лейкоз, с применением замещенных гетероциклических соединений и их фармацевтически приемлемых солей. Соединения ингибируют киназы IRAK4 и FLT-3.
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
IN201741011785 | 2017-03-31 | ||
PCT/IB2018/052232 WO2018178947A2 (en) | 2017-03-31 | 2018-03-30 | Compounds and compositions for treating hematological disorders |
Publications (2)
Publication Number | Publication Date |
---|---|
EA201992322A2 EA201992322A2 (ru) | 2020-07-31 |
EA201992322A3 true EA201992322A3 (ru) | 2020-09-30 |
Family
ID=63677680
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
EA201992322A EA201992322A3 (ru) | 2017-03-31 | 2018-03-30 | Соединения и композиции для лечения гематологических расстройств |
Country Status (24)
Country | Link |
---|---|
US (2) | US11419875B2 (ru) |
EP (2) | EP3600270B1 (ru) |
JP (2) | JP7333136B2 (ru) |
KR (2) | KR102633530B1 (ru) |
CN (1) | CN110691589A (ru) |
AU (2) | AU2018242623B2 (ru) |
BR (1) | BR112019018991A2 (ru) |
CA (1) | CA3056893A1 (ru) |
DK (1) | DK3600270T3 (ru) |
EA (1) | EA201992322A3 (ru) |
ES (1) | ES2950764T3 (ru) |
FI (1) | FI3600270T3 (ru) |
HR (1) | HRP20230657T8 (ru) |
HU (1) | HUE062648T2 (ru) |
IL (3) | IL305150A (ru) |
LT (1) | LT3600270T (ru) |
MX (2) | MX2019011158A (ru) |
PH (1) | PH12019502138A1 (ru) |
PL (1) | PL3600270T3 (ru) |
PT (1) | PT3600270T (ru) |
RS (1) | RS64411B1 (ru) |
SG (1) | SG11201908171TA (ru) |
SI (1) | SI3600270T1 (ru) |
WO (1) | WO2018178947A2 (ru) |
Families Citing this family (15)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
DK3466955T3 (da) * | 2014-01-13 | 2021-02-01 | Aurigene Discovery Tech Ltd | Fremgangsmåde til fremstilling af oxazol[4,5-b]pyridin og thiazol[4,5-b]pyridinderivater som irak4-hæmmere til behandling af cancer |
PL3600270T3 (pl) | 2017-03-31 | 2023-09-25 | Aurigene Oncology Limited | Związki i kompozycje do leczenia zaburzeń hematologicznych |
WO2019111218A1 (en) | 2017-12-08 | 2019-06-13 | Cadila Healthcare Limited | Novel heterocyclic compounds as irak4 inhibitors |
EP3998264A4 (en) * | 2019-07-10 | 2023-07-12 | Medshine Discovery Inc. | OXAZOLE COMPOUND AS A MULTI-TARGETED INHIBITOR OF IRAK4 AND BTK |
WO2021047677A1 (zh) * | 2019-09-12 | 2021-03-18 | 中国科学院上海药物研究所 | 一类irak4激酶抑制剂及其制备和应用 |
TW202142538A (zh) | 2020-02-07 | 2021-11-16 | 美商迦舒布魯姆生物有限公司 | 雜環glp-1促效劑 |
AU2021251341A1 (en) | 2020-04-07 | 2022-11-03 | Bayer Aktiengesellschaft | Substituted thiazolopyridines, salts thereof and their use as herbicidally active substances |
MX2023001296A (es) * | 2020-08-03 | 2023-02-22 | Curis Inc | Composiciones y metodos para tratar enfermedades y trastornos. |
WO2022135338A1 (zh) * | 2020-12-25 | 2022-06-30 | 南京明德新药研发有限公司 | 酰胺噁唑类化合物 |
AU2022254933A1 (en) * | 2021-04-08 | 2023-11-09 | Curis, Inc. | Combination therapies for the treatment of cancer |
CN113402499B (zh) | 2021-06-21 | 2022-05-13 | 上海勋和医药科技有限公司 | 一种亚磺酰亚胺取代的吲唑类irak4激酶抑制剂、制备方法及用途 |
TW202328151A (zh) | 2021-09-07 | 2023-07-16 | 德商拜耳廠股份有限公司 | 經取代之2,3-二氫[1,3]噻唑并[4,5-b]吡啶、其鹽及其作為除草活性物質之用途 |
TW202328150A (zh) | 2021-09-07 | 2023-07-16 | 德商拜耳廠股份有限公司 | 經取代之噻唑并吡啶、其鹽及其作為除草活性物質之用途 |
WO2023088435A1 (zh) * | 2021-11-19 | 2023-05-25 | 成都奥睿药业有限公司 | 三取代吡啶衍生物的制备及作为芳香烃受体调节物的应用 |
WO2023116866A1 (zh) * | 2021-12-23 | 2023-06-29 | 杭州多域生物技术有限公司 | 一种五元并六元化合物、制备方法、药物组合物和应用 |
Family Cites Families (75)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4172896A (en) | 1978-06-05 | 1979-10-30 | Dainippon Pharmaceutical Co., Ltd. | Methane-sulfonamide derivatives, the preparation thereof and composition comprising the same |
US5494911A (en) | 1990-05-18 | 1996-02-27 | Hoechst Aktiengesellschaft | Isoxazole-4-carboxamides and hydroxyalkylidenecyanoacetamides, pharmaceuticals containing these compounds and their use |
GB9217295D0 (en) | 1992-08-14 | 1992-09-30 | Wellcome Found | Controlled released tablets |
GB9315856D0 (en) | 1993-07-30 | 1993-09-15 | Wellcome Found | Stabilized pharmaceutical |
US5541231A (en) | 1993-07-30 | 1996-07-30 | Glaxo Wellcome Inc. | Stabilized Pharmaceutical |
US5358970A (en) | 1993-08-12 | 1994-10-25 | Burroughs Wellcome Co. | Pharmaceutical composition containing bupropion hydrochloride and a stabilizer |
PT999825E (pt) | 1997-07-29 | 2004-02-27 | Alcon Lab Inc | Composicoes oftalmicas contendo polimeros de galactomanano e borato |
AU2483599A (en) | 1998-01-29 | 1999-08-16 | Sepracor, Inc. | Pharmaceutical uses of optically pure (-)-bupropion |
US8889112B2 (en) | 1999-09-16 | 2014-11-18 | Ocularis Pharma, Llc | Ophthalmic formulations including selective alpha 1 antagonists |
DE10023486C1 (de) | 2000-05-09 | 2002-03-14 | Schering Ag | Ortho substituierte Anthranilsäureamide und deren Verwendung als Arzneimittel |
US6878714B2 (en) | 2001-01-12 | 2005-04-12 | Amgen Inc. | Substituted alkylamine derivatives and methods of use |
US20030134836A1 (en) | 2001-01-12 | 2003-07-17 | Amgen Inc. | Substituted arylamine derivatives and methods of use |
NZ543375A (en) | 2003-05-01 | 2009-05-31 | Bristol Myers Squibb Co | Aryl-substituted pyrazole-amide compounds useful as kinase inhibitors |
EP2281823A3 (en) | 2003-05-20 | 2011-09-07 | Ajinomoto Co., Inc. | Anti-inflammatory and analgesic piperidine derivatives |
US20050004133A1 (en) | 2003-06-05 | 2005-01-06 | Makings Lewis R. | Modulators of VR1 receptor |
US20050059744A1 (en) | 2003-09-12 | 2005-03-17 | Allergan, Inc. | Methods and compositions for the treatment of pain and other alpha 2 adrenergic-mediated conditions |
JP2007525482A (ja) | 2003-10-07 | 2007-09-06 | レノビス, インコーポレイテッド | イオンチャネルリガンドとしてのアミド化合物およびその使用 |
MXPA06012104A (es) | 2004-04-22 | 2007-01-25 | Bayer Cropscience Lp | Metodo y composicion para controlar malas hierbas. |
EP1655297A1 (en) | 2004-11-03 | 2006-05-10 | Schering Aktiengesellschaft | Nicotinamide pyridinureas as vascular endothelial growth factor (VEGF) receptor kinase inhibitors |
US7906533B2 (en) | 2004-11-03 | 2011-03-15 | Bayer Schering Pharma Ag | Nicotinamide pyridinureas as vascular endothelial growth factor (VEGF) receptor kinase inhibitors |
EP1819341A4 (en) | 2004-11-10 | 2011-06-29 | Synta Pharmaceuticals Corp | IL-12 MODULATORY CONNECTIONS |
ES2333243T3 (es) | 2004-12-17 | 2010-02-18 | Eli Lilly And Company | Derivados de tiazolopiridinona como antagonistas del receptor de mch. |
EP1828177B1 (en) * | 2004-12-17 | 2008-08-13 | Eli Lilly And Company | Novel mch receptor antagonists |
EP1674467A1 (en) | 2004-12-22 | 2006-06-28 | 4Sc Ag | 2,5- and 2,6-disubstituted benzazole derivatives useful as protein kinase inhibitors |
WO2007058626A1 (en) | 2005-11-16 | 2007-05-24 | S*Bio Pte Ltd | Indazole compounds |
EP1987028A2 (en) | 2006-02-10 | 2008-11-05 | Transtech Pharma, Inc. | Benzazole derivatives, compositions, and methods of use as aurora kinase inhibitors |
GB0606429D0 (en) | 2006-03-30 | 2006-05-10 | Novartis Ag | Organic compounds |
US8008481B2 (en) | 2006-03-31 | 2011-08-30 | Ericsson Anna M | Indazole compounds |
US20080293785A1 (en) | 2006-04-11 | 2008-11-27 | Connolly Peter J | Substituted benzothiazole kinase inhibitors |
CN101594909A (zh) | 2006-09-07 | 2009-12-02 | 比奥根艾迪克Ma公司 | 用于治疗炎性病症、细胞增殖性失调、免疫失调的irak调节剂 |
NZ575410A (en) | 2006-09-07 | 2012-03-30 | Biogen Idec Inc | 2-(1H-Indazol-3-ylamino)-1H-benzimidazole derivatives |
WO2008061109A2 (en) | 2006-11-15 | 2008-05-22 | Forest Laboratories Holdings Limited | Indazole derivatives useful as melanin concentrating receptor ligands |
JP5399262B2 (ja) | 2006-12-08 | 2014-01-29 | エグゼリクシス パテント カンパニー エルエルシー | Lxrおよびfxrのモジュレーター |
JP4785881B2 (ja) | 2007-02-27 | 2011-10-05 | 大塚製薬株式会社 | 医薬 |
EP2170892A2 (en) * | 2007-06-14 | 2010-04-07 | Schering Corporation | Imidazopyrazines as protein kinase inhibitors |
CN101754955A (zh) | 2007-07-16 | 2010-06-23 | 雅培制药有限公司 | 作为蛋白激酶抑制剂的吲唑、苯并异*唑和苯并异噻唑化合物 |
US20090069288A1 (en) | 2007-07-16 | 2009-03-12 | Breinlinger Eric C | Novel therapeutic compounds |
US8399448B2 (en) | 2007-08-08 | 2013-03-19 | Merck Serono Sa | 6-amino-pyrimidine-4-carboxamide derivatives and related compounds which bind to the sphingosine 1-phosphate (S1P) receptor for the treatment of multiple sclerosis |
JP5496915B2 (ja) | 2008-02-13 | 2014-05-21 | シージーアイ ファーマシューティカルズ,インコーポレーテッド | 6−アリール−イミダゾ[1,2−a]ピラジン誘導体、その製造方法、及びその使用方法 |
EP2303886A2 (en) * | 2008-06-24 | 2011-04-06 | Takeda Pharmaceutical Company Limited | Pi3k/m tor inhibitors |
AU2009316786A1 (en) | 2008-11-19 | 2010-05-27 | Merck Sharp & Dohme Corp. | Inhibitors of diacylglycerol acyltransferase |
EP2379564A1 (en) | 2008-12-19 | 2011-10-26 | Schering Corporation | Bicyclic heterocyclic derivatives and methods of use thereof |
CN102264701A (zh) | 2008-12-23 | 2011-11-30 | 霍夫曼-拉罗奇有限公司 | 作为p2x7调节剂的二氢吡啶酮脲 |
WO2010144909A1 (en) * | 2009-06-12 | 2010-12-16 | Novartis Ag | Fused heterocyclic compounds and their uses |
CA2770454A1 (en) | 2009-08-19 | 2011-02-24 | Ambit Biosciences Corporation | Biaryl compounds and methods of use thereof |
JP5819305B2 (ja) | 2009-10-13 | 2015-11-24 | リガンド・ファーマシューティカルズ・インコーポレイテッド | 造血成長因子模倣小分子化合物およびそれらの使用 |
AU2011242711C1 (en) | 2010-04-22 | 2016-04-21 | Janssen Pharmaceutica Nv | Indazole compounds useful as ketohexokinase inhibitors |
US20130053382A1 (en) | 2010-04-30 | 2013-02-28 | Sunil Paliwal | Inhibitors of Phosphoinositide Dependent Kinase 1 (PDK1) |
CN103068385B (zh) | 2010-06-24 | 2015-04-29 | 凯莫森特里克斯股份有限公司 | C5aR拮抗剂 |
CA2802641C (en) | 2010-07-13 | 2019-03-12 | Nidhi Arora | Pyrazolo [1, 5a] pyrimidine and thieno [3, 2b] pyrimidine derivatives as irak4 modulators |
PT2730564T (pt) | 2010-11-19 | 2018-07-24 | Ligand Pharm Inc | Aminas heterocíclicas e suas utilizações |
HUE029617T2 (en) | 2010-12-20 | 2017-03-28 | Merck Serono Sa | Indazolyl triazole derivatives as IRAK inhibitors |
WO2012142125A2 (en) | 2011-04-12 | 2012-10-18 | The United States Of America, As Represented By The Secretary, Department Of Health And Human Services | Plasmodial surface anion channel inhibitors for the treatment or prevention of malaria |
WO2013042137A1 (en) | 2011-09-19 | 2013-03-28 | Aurigene Discovery Technologies Limited | Bicyclic heterocycles as irak4 inhibitors |
JP6162130B2 (ja) * | 2011-10-14 | 2017-07-12 | アムビト ビオスシエンセス コルポラチオン | Iii型受容体チロシンキナーゼの調節因子としての複素環式化合物及びその使用 |
CN104394869A (zh) | 2011-10-20 | 2015-03-04 | 葛兰素史密斯克莱有限责任公司 | 用作沉默调节蛋白调节剂的取代的双环氮杂杂环化合物和类似物 |
GB201119401D0 (en) | 2011-11-10 | 2011-12-21 | Ucb Pharma Sa | Therapeutic agents |
KR101385603B1 (ko) | 2012-05-17 | 2014-04-21 | 한국원자력의학원 | 벤조티아졸 유도체 및 암 치료를 위한 그의 용도 |
WO2014003483A1 (en) | 2012-06-29 | 2014-01-03 | Hanmi Pharm. Co., Ltd. | Fused pyrimidine derivatives having inhibitory activity on fms kinases |
US9085586B2 (en) | 2012-07-11 | 2015-07-21 | Nimbus Iris, Inc. | IRAK inhibitors and uses thereof |
JP6372666B2 (ja) | 2012-11-03 | 2018-08-15 | ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング | サイトメガロウイルスの阻害剤 |
EP2999470B1 (en) | 2013-05-22 | 2017-08-16 | Children's Hospital Medical Center | Combination therapy for mds |
TWI652014B (zh) | 2013-09-13 | 2019-03-01 | 美商艾佛艾姆希公司 | 雜環取代之雙環唑殺蟲劑 |
TWI667233B (zh) | 2013-12-19 | 2019-08-01 | 德商拜耳製藥公司 | 新穎吲唑羧醯胺,其製備方法、含彼等之醫藥製劑及其製造醫藥之用途 |
EP3092226B1 (en) | 2014-01-10 | 2019-03-13 | Aurigene Discovery Technologies Limited | Indazole compounds as irak4 inhibitors |
DK3466955T3 (da) * | 2014-01-13 | 2021-02-01 | Aurigene Discovery Tech Ltd | Fremgangsmåde til fremstilling af oxazol[4,5-b]pyridin og thiazol[4,5-b]pyridinderivater som irak4-hæmmere til behandling af cancer |
BR112016017996A2 (pt) | 2014-02-06 | 2017-08-08 | Abbvie Inc | 6-heteroariloxi- or 6-ariloxi-quinolina-2-carboxamidas e método de uso |
EA201692418A1 (ru) | 2014-06-20 | 2017-04-28 | Ауриджен Дискавери Текнолоджиз Лимитед | Замещенные индазольные соединения в качестве irak4 ингибиторов |
JO3705B1 (ar) | 2014-11-26 | 2021-01-31 | Bayer Pharma AG | إندازولات مستبدلة جديدة، عمليات لتحضيرها، مستحضرات دوائية تحتوي عليها واستخدامها في إنتاج أدوية |
EA201890307A1 (ru) | 2015-07-15 | 2018-10-31 | Ориджин Дискавери Текнолоджиз Лимитед | Индазольные и азаиндазольные соединения как ингибиторы irak-4 |
WO2017009806A1 (en) * | 2015-07-15 | 2017-01-19 | Aurigene Discovery Technologies Limited | Substituted aza compounds as irak-4 inhibitors |
EP3719016A1 (en) | 2015-08-04 | 2020-10-07 | Rigel Pharmaceuticals, Inc. | Benzazole compounds and methods for making and using the compounds |
CA3038130A1 (en) | 2016-10-28 | 2018-05-03 | Children's Hospital Medical Center | Treatment of diseases associated with activated irak |
PL3600270T3 (pl) | 2017-03-31 | 2023-09-25 | Aurigene Oncology Limited | Związki i kompozycje do leczenia zaburzeń hematologicznych |
EP3704108B1 (en) | 2017-10-31 | 2024-04-24 | Curis, Inc. | Irak4 inhibitor in combination with a bcl-2 inhibitor for use in treating cancer |
-
2018
- 2018-03-30 PL PL18777745.3T patent/PL3600270T3/pl unknown
- 2018-03-30 KR KR1020197032104A patent/KR102633530B1/ko active IP Right Grant
- 2018-03-30 BR BR112019018991A patent/BR112019018991A2/pt unknown
- 2018-03-30 IL IL305150A patent/IL305150A/en unknown
- 2018-03-30 HR HRP20230657TT patent/HRP20230657T8/hr unknown
- 2018-03-30 IL IL269536A patent/IL269536B/en unknown
- 2018-03-30 KR KR1020247003678A patent/KR20240019391A/ko active Application Filing
- 2018-03-30 CA CA3056893A patent/CA3056893A1/en active Pending
- 2018-03-30 CN CN201880022870.5A patent/CN110691589A/zh active Pending
- 2018-03-30 SI SI201830946T patent/SI3600270T1/sl unknown
- 2018-03-30 MX MX2019011158A patent/MX2019011158A/es unknown
- 2018-03-30 US US16/498,866 patent/US11419875B2/en active Active
- 2018-03-30 EP EP18777745.3A patent/EP3600270B1/en active Active
- 2018-03-30 SG SG11201908171T patent/SG11201908171TA/en unknown
- 2018-03-30 EA EA201992322A patent/EA201992322A3/ru unknown
- 2018-03-30 EP EP23173240.5A patent/EP4252853A3/en active Pending
- 2018-03-30 IL IL293783A patent/IL293783B2/en unknown
- 2018-03-30 LT LTEPPCT/IB2018/052232T patent/LT3600270T/lt unknown
- 2018-03-30 DK DK18777745.3T patent/DK3600270T3/da active
- 2018-03-30 HU HUE18777745A patent/HUE062648T2/hu unknown
- 2018-03-30 JP JP2019552983A patent/JP7333136B2/ja active Active
- 2018-03-30 PT PT187777453T patent/PT3600270T/pt unknown
- 2018-03-30 ES ES18777745T patent/ES2950764T3/es active Active
- 2018-03-30 WO PCT/IB2018/052232 patent/WO2018178947A2/en active Application Filing
- 2018-03-30 AU AU2018242623A patent/AU2018242623B2/en active Active
- 2018-03-30 FI FIEP18777745.3T patent/FI3600270T3/fi active
- 2018-03-30 RS RS20230544A patent/RS64411B1/sr unknown
-
2019
- 2019-09-18 PH PH12019502138A patent/PH12019502138A1/en unknown
- 2019-09-19 MX MX2022001343A patent/MX2022001343A/es unknown
-
2022
- 2022-06-29 US US17/853,299 patent/US20220339161A1/en active Pending
-
2023
- 2023-08-09 JP JP2023129903A patent/JP2023154005A/ja not_active Withdrawn
-
2024
- 2024-06-11 AU AU2024203943A patent/AU2024203943A1/en active Pending
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
EA201992322A3 (ru) | Соединения и композиции для лечения гематологических расстройств | |
SA520420458B1 (ar) | نظائر رابامايسين مرتبطة بـ C40، C28، وC32 mTOR كمثبطات | |
MX2023007581A (es) | Analogos de rapamicina unidos a c26 como inhibidores de mtor. | |
PH12018502102A1 (en) | Pyrrolotriazine compounds as tam inhibitors | |
EA201991198A1 (ru) | АМИНОТИАЗОЛЬНЫЕ СОЕДИНЕНИЯ В КАЧЕСТВЕ ИНГИБИТОРОВ c-Kit | |
PH12018500041A1 (en) | Substituted aza compoounds as irak-4 inhibitors | |
EA202092442A3 (ru) | Новые гетероциклические производные, применимые в качестве ингибиторов shp2 | |
EA201891910A1 (ru) | Гетероарильные ингибиторы pad4 | |
EA201991197A1 (ru) | БЕНЗИМИДАЗОЛЬНЫЕ СОЕДИНЕНИЯ В КАЧЕСТВЕ ИНГИБИТОРОВ c-Kit | |
EA202090497A1 (ru) | Соединения и композиции для лечения гематологических нарушений | |
MD20170016A2 (ru) | Аминопиримидиновые соединения в качестве ингибиторов JAK | |
EA201691302A1 (ru) | Новые гетероциклические соединения | |
EA201592199A1 (ru) | Производные бипиразола в качестве ингибиторов jak | |
EA201891251A1 (ru) | Бициклические ингибиторы pad4 | |
EA201692268A1 (ru) | Ингибиторы фосфатидилинозитол-3-киназы | |
MX2020001757A (es) | Compuestos, sales de los mismos y metodos para el tratamiento de enfermedades. | |
EA201692114A1 (ru) | Замещенные дигидроизохинолиноновые соединения | |
EA201692267A1 (ru) | Ингибиторы фосфатидилинозитол-3-киназы | |
MX2018012085A (es) | Compuestos agonistas de gpr119 y metodo para tratar enfermedades y afecciones mediado a traves de gpr119. | |
UY37466A (es) | N-hidroxiamidinheterociclos sustituidos como moduladores de la indolamina 2,3-dioxigenasa | |
EA201891347A1 (ru) | Аза-бензимидазольные ингибиторы pad4 | |
EA201692260A1 (ru) | Соединения 1,3,4-тиадиазола и их применение в лечении рака | |
EA201792425A1 (ru) | Трициклические соединения и их применение в качестве ингибиторов фосфодиэстераз | |
EA202190464A1 (ru) | Замещенные бензимидазолы в качестве ингибиторов pad4 | |
PH12020551343A1 (en) | 7-substituted sulfonimidoylpurinone compounds and derivatives for the treatment and prophylaxis of liver cancer |